

CPSA 6 (b)(1) Cleared

[Signature]
No Mfrs, Products or
Products Identified
Excepted by _____
Firms Notified,
Comments Processed.

MEETING LOG

Patricia M. Bittner
Co-Chair, Hazard/Risk Assessment Platform Session
Annual Meeting of the Teratology Society
June 27, 2000
Palm Beach, Florida

This was a platform session at the Teratology Annual Meeting, which ran from June 25-29, 2000. Basic scientific data were presented. No data of substantial interest to the CPSC were presented. Approximately 100 attendees, primarily members of the Teratology Society, in the session; approximately 600 attendees at the meeting.

A copy of the Hazard/Risk Assessment Platform Session is attached.



TRANYLCPROMINE IN TWO CONSECUTIVE PREGNANCIES

D.S. Kennedy¹, N. Evans¹, I. Wang¹, and W.S. Webster², ¹Royal Prince Alfred Hospital and ²The University of Sydney, Sydney, Australia

1:00 pm–2:15 pm 16 MATERNAL ALCOHOL CONSUMPTION AND INTRAUTERINE GROWTH RETARDATION: A POPULATION-BASED CASE-CONTROL STUDY

Q.H. Yang¹, B.B. Witkiewicz², R.S. Olney¹, Y.C. Liu¹, M. Davis¹, M.J. Khoury¹, A. Correa¹, and J.D. Erickson¹, ¹Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; ²Monroe County Department of Health, Rochester, New York

2:15 pm–2:30 pm 17 PROSPECTIVE PREGNANCY OUTCOME IN WOMEN EXPOSED TO AMPHETAMINES

R.J. Felix, C.D. Chambers, L.M. Dick, K.A. Johnson, and K.L. Jones, Department of Pediatrics, Division of Dysmorphology and Teratology, University of California San Diego, La Jolla, California

2:30 pm–4:00 pm Platform IIb: Teratology Society/OTIS Joint Session 2

Chairpersons: Kathie Johnson, California Teratogen Information Service, Department of Pediatrics, UCSD, San Diego, California and Jan Freidman, University of British Columbia, Vancouver, Canada

2:30 pm–2:45 pm 18 DESIGN OF A DATABASE OF HUMAN PRENATAL DRUG EXPOSURES ASSOCIATED WITH ADVERSE DEVELOPMENTAL OUTCOMES REPORTED TO FDA

A. Vega¹ and S. Tabacova², ¹CDER/FDA and ²NCTR/ FDA, Rockville, Maryland

2:45 pm–3:00 pm 19 ACCUTANE® - EXPOSED PREGNANCIES

M.A. Honein and L. J. Paulozzi, Centers for Disease Control and Prevention, Atlanta, Georgia

3:00 pm –3:15 pm 20 CONFIDENTIALITY AND DISCLOSURE ISSUES IN COUNSELING PREGNANT PATIENTS WHO REVEAL SUBSTANCE ABUSE: A CASE REPORT

K. Filkins¹, S. Beverly¹, E. Chen¹, D. Johnstone², J. Gordon², and N. Catalano³, ¹UCLA School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, California; ²UCLA School of Medicine, Department of Clinical Social Work, Los Angeles, California; ³California Teratogen Information Service, University of California, San Diego Medical Center

3:15 pm–3:30 pm 21 DOES DRUG LABELING INFLUENCE RISK PERCEPTIONS OF TERATOGENICITY? A SURVEY OF PREGNANT WOMEN AND THEIR HEALTH PROFESSIONALS

A. Einarson¹, M. Pole¹, T.R. Einarson², N. Pairadeau³, and G. Koren¹, ¹The Motherisk Program, The Hospital for Sick Children, ²Faculty of Pharmacy, University of Toronto, and ³Obstetrics Dept, North York General Hospital, Toronto, Canada

3:30 pm–4:00 pm 22 SELF-SELECTION BIAS IN TERATOLOGY INFORMATION SERVICE PREGNANCY OUTCOME STUDIES

K.A. Johnson¹, P.A. Weber², C.D. Chambers¹, and K.L. Jones¹, ¹Department of Pediatrics, Division of Dysmorphology and Teratology, University of California San Diego, La Jolla, California and ²Kaiser Permanente of Southern California, San Diego, California

* 1:00 pm–4:00 pm Platform III Session — Ponce De Leon I

1:00 pm–2:30 pm Platform IIIa: Hazard/Risk Assessment Session 1

Chairpersons: James Schardein, WIL Research Laboratories, Ashland, Ohio and Patricia Bittner, Consumer Product Safety Commission, Washington, District of Columbia

1:00 pm–1:15 pm 23 DEVELOPMENTAL TOXICITY INTERACTIONS OF METHANOL AND

RADIOFREQUENCY (RF) RADIATION OR 2-METHOXYETHANOL (2ME) IN RATS
B.K. Nelson, D.L. Snyder, and P.B. Shaw, Division of Biomedical and Behavioral Science, NIOSH, Cincinnati, Ohio

11:15 pm-1:30 pm 24 **ADDITIVITY OF CARBON MONOXIDE AND PROTEIN DEFICIENCY ON NEONATAL MORTALITY IN MICE**
J. Singh, Stillman College, Tuscaloosa, Alabama

1:30 pm-1:45 pm 25 **THE PREDOMINANT ROLE OF MATERNAL TOXICITY IN LOVASTATIN-INDUCED DEVELOPMENTAL TOXICITY**
L.D. Wise, M.A. Cukierski, G.R. Lankas, and G.L. Skiles, Merck Research Laboratories, West Point, Pennsylvania

1:45 pm-2:00 pm 26 **PREGNANCY ALTERS THE PHARMACOKINETICS OF CYSTEAMINE IN THE PREGNANT RAT AND EFFECTS POSTNATAL DEVELOPMENT**
L.B. Fawcett, D.A. Beckman, L.K. Sherrell, J.E. Pugarelli, and F.K. Assadi, Department of Medical Cell Biology, Alfred I. duPont Hospital for Children, Wilmington, Delaware

2:00 pm-2:15 pm 27 **LEFLUNOMIDE AS AN EXAMPLE OF A MODERN APPROACH TO PRODUCT LABELING FOR REPRODUCTIVE EFFECTS: A CATEGORY X DRUG BASED ON PHARMACOKINETIC DATA**
R.L. Brent, duPont Hospital for Children, Wilmington, Delaware

2:15 pm-2:30 pm 28 **THE EFFECTS OF IN UTERO EXPOSURE TO A LOW DOSE OF BISPHENOL A ON FEMALE SEXUAL MATURATION OF THE RAT**
C.E. Talsness and I. Chahoud, Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Freie Universitaet, Berlin, Germany

2:30 pm-4:00 pm Platform IIIb: Hazard/Risk Assessment Session 2

Chairpersons: Ed Carney, Dow Chemical Company, Midland, Michigan and Steve Harris, The Steve Harris Group, San Diego, California

2:30 pm-2:45 pm 29 **A THREE-DIMENSIONAL CULTURE SYSTEM SUPPORTS DEVELOPMENT OF INCISORS AND MOLARS IN MAXILLA AND MANDIBLE OF CULTURED MURINE FIRST ARCHES**
P. Williams, D. Montufar-Solis, and J. Duke, Dept. of Orthodontics, Dental Branch, UT Houston Health Science Center, Houston, Texas

2:45 pm-3:00 pm 30 **THE MECHANISM OF CLEFT PALATE FORMATION IN THE CHONDRODYSPLASIA MOUSE**
W. McLean^{1,4}, I.G. Lavrin², R.E. Seegmiller³, C.W. Archer⁴, E.D. Hay¹, and B.R. Olsen¹, ¹Harvard Medical School and ²Harvard School of Dental Medicine, Boston, Massachusetts; ³Brigham Young University, Provo, Utah; ⁴Cardiff University, Cardiff, UK

3:00 pm-3:15 pm 31 **DEVELOPMENTAL TOXICITY STUDIES WITH GLYPHOSATE AND SELECTED SURFACTANTS IN RATS**
D.R. Farmer, T.A. Kaempfe, W.F. Heydens, and W.R. Kelce, Monsanto Company, St. Louis, Missouri

3:15 pm-3:30 pm 32 **RIO GRANDE RIVER WATER AND SEDIMENT EXTRACTS INDUCE NEURAL TUBE DEFECTS (NTD) IN XENOPUS**

J. Fort¹, E.L. Stover¹, J.A. Bantle², and J.G. Burkhardt³, ¹The Stover Group, Stillwater, Oklahoma; ²Oklahoma State University Department of Zoology, Stillwater, Oklahoma; ³NIEHS, Research Triangle Park, North Carolina